Agilent Technologies Microarrays Used in Groundbreaking Prenatal Research Study
News Dec 10, 2012
The three-year collaborative study, "Chromosomal microarray versus karyotyping for prenatal diagnosis," represents a significant milestone in understanding prenatal abnormalities. Agilent SurePrint CGH microarrays were used for the majority of the 4,400 cohort samples. Use of this technology enabled researchers to detect smaller aberrations compared to traditional karyotyping.
Researchers from Emory University, Baylor College of Medicine, Columbia University and Signature Genomics collaborated in this study. Their primary objective was to evaluate the accuracy, efficacy and potential advantages of using microarray analysis compared with conventional karyotyping. Their secondary objective was to evaluate analytical performance. The study was sponsored by the National Institute of Child Health and Human Development.
Agilent was the primary contributor of microarrays and reagents used in this study; 71 percent of samples were run on Agilent SurePrint CGH microarrays. Agilent assisted investigators in developing customized arrays for the study.
"We are honored to have participated in this landmark study, furthering technology adoption for improved discovery," said Robert Schueren, vice president and general manager of Agilent's Genomics Solutions Division.
A total of 5,500 arrays were used. The majority of the samples were composed of uncultured amniotic fluid and chorionic villi. All samples were also sent to a reference lab for chromosome analysis. All data was submitted to the National Center for Biotechnology Information and is available to the public free of charge.
Agilent's custom microarrays are manufactured to customer-specified designs. They are not approved or cleared by the U.S. Food and Drug Administration for use in diagnostic procedures. Customers are responsible for FDA approval/clearance prior to diagnostic use.
New Rapid Test for Valley Fever Should Help Reduce Diagnosis DelaysNews
November saw a spike if cases of Valley fever. Fortunately, the recent—and timely—approval of a new rapid assay test for Valley fever should reduce delays in diagnosing the respiratory fungal infections—a frequent problem in treating the disease, which is caused by spores endemic to soils in the U.S. Southwest.READ MORE
Should Historic Doping Issues Strip All Athletes of World Records?News
A proposal had been put forward by the European Athletics Council to disregard all world records set before 2005 due to issues with doping. However, a recent publication suggests these plans should be abolished.READ MORE
Infrared Spectroscopy Test Can Diagnose Two Cancer TypesNews
Researchers used mid-infrared spectroscopy to analyze blood serum derived from experimental mice and differentiate mice with non-Hodgkin’s lymphoma and subcutaneous melanoma from healthy mice and also between these two tumorous conditions.READ MORE